NO329997B1 - Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr. - Google Patents

Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr. Download PDF

Info

Publication number: NO329997B1
Authority: NO; Norway
Prior art keywords: tai; pharmaceutical preparation; mammal; cells; dcs
Prior art date: 2003-03-28

Application number

NO20054912A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054912D0 (no

NO20054912L (no

Inventor

Guido Rasi

Enrico Garaci

Francesco Bistoni

Luigina Romani

Paolo Di Firancesco

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-28

Filing date

2005-10-24

Publication date

2011-02-07

2005-10-24 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2005-10-24 Publication of NO20054912D0 publication Critical patent/NO20054912D0/no

2005-12-20 Publication of NO20054912L publication Critical patent/NO20054912L/no

2011-02-07 Publication of NO329997B1 publication Critical patent/NO329997B1/no

Links

201000002909 Aspergillosis Diseases 0.000 title claims description 13
208000036641 Aspergillus infections Diseases 0.000 title claims description 13
241000124008 Mammalia Species 0.000 title claims description 13
238000002360 preparation method Methods 0.000 title claims description 6
239000008194 pharmaceutical composition Substances 0.000 title 1
108010078233 Thymalfasin Proteins 0.000 claims abstract description 53
102400000800 Thymosin alpha-1 Human genes 0.000 claims abstract description 53
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims abstract description 53
229960004231 thymalfasin Drugs 0.000 claims abstract description 53
210000004443 dendritic cell Anatomy 0.000 claims abstract description 40
206010061598 Immunodeficiency Diseases 0.000 claims abstract description 5
238000011282 treatment Methods 0.000 claims description 29
239000000825 pharmaceutical preparation Substances 0.000 claims description 19
230000000843 anti-fungal effect Effects 0.000 claims description 14
201000009085 invasive aspergillosis Diseases 0.000 claims description 14
229940121375 antifungal agent Drugs 0.000 claims description 10
230000002265 prevention Effects 0.000 claims description 8
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 6
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 6
229960003942 amphotericin b Drugs 0.000 claims description 6
102000004127 Cytokines Human genes 0.000 claims description 5
108090000695 Cytokines Proteins 0.000 claims description 5
230000037396 body weight Effects 0.000 claims description 4
108010046075 Thymosin Proteins 0.000 claims description 3
102000007501 Thymosin Human genes 0.000 claims description 3
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 3
239000003429 antifungal agent Substances 0.000 claims 2
210000001185 bone marrow Anatomy 0.000 claims 1
241000228212 Aspergillus Species 0.000 abstract description 16
208000015181 infectious disease Diseases 0.000 abstract description 16
238000010322 bone marrow transplantation Methods 0.000 abstract description 15
238000000034 method Methods 0.000 abstract description 4
230000003213 activating effect Effects 0.000 abstract description 2
241000699670 Mus sp. Species 0.000 description 30
210000004027 cell Anatomy 0.000 description 26
102000002689 Toll-like receptor Human genes 0.000 description 20
108020000411 Toll-like receptor Proteins 0.000 description 20
210000004072 lung Anatomy 0.000 description 16
230000004044 response Effects 0.000 description 16
102000008235 Toll-Like Receptor 9 Human genes 0.000 description 15
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 14
230000000694 effects Effects 0.000 description 14
238000004519 manufacturing process Methods 0.000 description 13
108010065805 Interleukin-12 Proteins 0.000 description 12
102000013462 Interleukin-12 Human genes 0.000 description 12
230000014509 gene expression Effects 0.000 description 11
230000037361 pathway Effects 0.000 description 11
210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
230000011664 signaling Effects 0.000 description 11
102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 10
108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 10
230000002538 fungal effect Effects 0.000 description 10
239000003446 ligand Substances 0.000 description 10
210000000440 neutrophil Anatomy 0.000 description 10
230000001419 dependent effect Effects 0.000 description 9
102000006992 Interferon-alpha Human genes 0.000 description 8
108010047761 Interferon-alpha Proteins 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000002950 deficient Effects 0.000 description 7
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 7
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 7
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 7
241000233866 Fungi Species 0.000 description 6
102000003814 Interleukin-10 Human genes 0.000 description 6
108090000174 Interleukin-10 Proteins 0.000 description 6
108090001007 Interleukin-8 Proteins 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
239000002158 endotoxin Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
108090000978 Interleukin-4 Proteins 0.000 description 5
108010057466 NF-kappa B Proteins 0.000 description 5
102000003945 NF-kappa B Human genes 0.000 description 5
206010057249 Phagocytosis Diseases 0.000 description 5
239000012636 effector Substances 0.000 description 5
230000008782 phagocytosis Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
102100037850 Interferon gamma Human genes 0.000 description 4
108010074328 Interferon-gamma Proteins 0.000 description 4
102000043136 MAP kinase family Human genes 0.000 description 4
108091054455 MAP kinase family Proteins 0.000 description 4
229920000392 Zymosan Polymers 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000031261 interleukin-10 production Effects 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
210000005174 lung dendritic cell Anatomy 0.000 description 4
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
102000043131 MHC class II family Human genes 0.000 description 3
108091054438 MHC class II family Proteins 0.000 description 3
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
210000000447 Th1 cell Anatomy 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229960004397 cyclophosphamide Drugs 0.000 description 3
230000016396 cytokine production Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
229960002442 glucosamine Drugs 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000004957 immunoregulator effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000005007 innate immune system Anatomy 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
208000004235 neutropenia Diseases 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
229920002101 Chitin Polymers 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
210000004241 Th2 cell Anatomy 0.000 description 2
102100039357 Toll-like receptor 5 Human genes 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
210000005006 adaptive immune system Anatomy 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
230000021995 interleukin-8 production Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000007898 magnetic cell sorting Methods 0.000 description 2
230000035800 maturation Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000005937 nuclear translocation Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
230000037452 priming Effects 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
STMRGLKPBJVVEG-UHFFFAOYSA-N 2-(2-oxopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CC(=O)C)C(=O)C2=C1 STMRGLKPBJVVEG-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241000758250 Aspergillus fumigatus A1163 Species 0.000 description 1
108010021800 B7-2 Antigen Proteins 0.000 description 1
102000007697 B7-2 Antigen Human genes 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010063916 CD40 Antigens Proteins 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
101000777452 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
101000800479 Homo sapiens Toll-like receptor 9 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
241000239218 Limulus Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
102000035181 adaptor proteins Human genes 0.000 description 1
108091005764 adaptor proteins Proteins 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000006041 cell recruitment Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000001378 electrochemiluminescence detection Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
102000046418 human ADAM11 Human genes 0.000 description 1
102000045718 human TLR2 Human genes 0.000 description 1
102000045717 human TLR4 Human genes 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000008975 immunomodulatory function Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
229950000038 interferon alfa Drugs 0.000 description 1
230000011488 interferon-alpha production Effects 0.000 description 1
230000019734 interleukin-12 production Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
102000005309 phosducin Human genes 0.000 description 1
108010031256 phosducin Proteins 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000020884 susceptibility to aspergillosis Diseases 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20054912A 2003-03-28 2005-10-24 Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr. NO329997B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45791103P	2003-03-28	2003-03-28
PCT/US2004/009550 WO2004087067A2 (fr)	2003-03-28	2004-03-29	Traitement d'infections par aspergillus a l'aide de thymosine alpha 1

Publications (3)

Publication Number	Publication Date
NO20054912D0 NO20054912D0 (no)	2005-10-24
NO20054912L NO20054912L (no)	2005-12-20
NO329997B1 true NO329997B1 (no)	2011-02-07

Family

ID=42828702

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054912A NO329997B1 (no)	2003-03-28	2005-10-24	Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr.

Country Status (17)

Country	Link
US (2)	US8207294B2 (fr)
EP (1)	EP1613340B1 (fr)
JP (1)	JP4629033B2 (fr)
KR (1)	KR101089145B1 (fr)
AT (1)	ATE467422T1 (fr)
AU (1)	AU2004226403B2 (fr)
BR (1)	BRPI0408892A (fr)
CA (1)	CA2520400C (fr)
DK (1)	DK1613340T3 (fr)
EA (1)	EA008037B1 (fr)
IL (1)	IL171118A (fr)
MX (1)	MXPA05010391A (fr)
NO (1)	NO329997B1 (fr)
NZ (1)	NZ542900A (fr)
PL (1)	PL1613340T3 (fr)
UA (1)	UA80870C2 (fr)
WO (1)	WO2004087067A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1613340T3 (da)	2003-03-28	2010-08-30	Sciclone Pharmaceuticals Inc	Behandling af aspergillus-infektioner med thymosin alfa 1
MX2007006717A (es) *	2004-12-06	2007-08-06	Sciclone Pharmaceuticals Inc	Peptidos de alfa timocina como adyuvantes en vacunas contra el cancer.
JP2009537584A (ja) *	2006-05-19	2009-10-29	シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ	免疫学的疾患の処置のためのチモシンα１の使用
ITRM20060583A1 (it) *	2006-10-27	2008-04-28	Francesco Bistoni	Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
US20140213506A1 (en) *	2011-02-09	2014-07-31	Cynthia W. TUTHILL	Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
AU2016217473B2 (en) *	2015-02-09	2021-07-29	Sciclone Pharmaceuticals International (Sg) Pte. Ltd.	Thymosin alpha 1 for use in treatment of cystic fibrosis
ITUB20153714A1 (it) *	2015-09-18	2017-03-18	Luigina Romani	Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4002740A (en) *	1975-08-21	1977-01-11	Gideon Goldstein	Tridecapeptide compositions and methods
US4079127A (en) *	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en) *	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
DE2919592A1 (de) *	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4612365A (en) *	1980-03-25	1986-09-16	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften	Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4374197A (en) *	1980-10-30	1983-02-15	Hoffmann-La Rocche Inc.	Process for thymosin α1
TW224053B (fr)	1991-09-13	1994-05-21	Paul B Chretien
CN1058500C (zh) *	1993-02-03	2000-11-15	施塞克龙药品公司	胸腺素α－1衍生物
CN1072961C (zh)	1993-03-05	2001-10-17	施塞克龙药品公司	治疗对干扰素治疗无反应者的丙型肝炎的方法
TW252045B (fr) *	1993-10-07	1995-07-21	Allan L Goldstein
RU2107692C1 (ru) *	1995-06-07	1998-03-27	Дейгин Владислав Исакович	Пептид и способ его получения
US5888980A (en) *	1994-06-30	1999-03-30	Bio-Logic Research And Development Corporation	Compositions for enhancing immune function
US5632983A (en)	1994-11-17	1997-05-27	University Of South Florida	Method for treating secondary immunodeficiency
WO1998035696A1 (fr) *	1997-02-18	1998-08-20	Sciclone Pharmaceuticals, Inc.	Utilisation de thymosine alpha 1 pour la fabrication d'un medicament destine a favoriser le developpement de cellules souches
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide
DK1613340T3 (da)	2003-03-28	2010-08-30	Sciclone Pharmaceuticals Inc	Behandling af aspergillus-infektioner med thymosin alfa 1

2004
- 2004-03-29 DK DK04749495.0T patent/DK1613340T3/da active
- 2004-03-29 EP EP04749495A patent/EP1613340B1/fr not_active Expired - Lifetime
- 2004-03-29 NZ NZ542900A patent/NZ542900A/en not_active IP Right Cessation
- 2004-03-29 BR BRPI0408892-1A patent/BRPI0408892A/pt not_active IP Right Cessation
- 2004-03-29 EA EA200501414A patent/EA008037B1/ru not_active IP Right Cessation
- 2004-03-29 UA UAA200509921A patent/UA80870C2/xx unknown
- 2004-03-29 CA CA2520400A patent/CA2520400C/fr not_active Expired - Lifetime
- 2004-03-29 AU AU2004226403A patent/AU2004226403B2/en not_active Ceased
- 2004-03-29 WO PCT/US2004/009550 patent/WO2004087067A2/fr not_active Ceased
- 2004-03-29 KR KR1020057018335A patent/KR101089145B1/ko not_active Expired - Fee Related
- 2004-03-29 AT AT04749495T patent/ATE467422T1/de active
- 2004-03-29 PL PL04749495T patent/PL1613340T3/pl unknown
- 2004-03-29 US US10/551,341 patent/US8207294B2/en active Active
- 2004-03-29 JP JP2006509423A patent/JP4629033B2/ja not_active Expired - Lifetime
- 2004-03-29 MX MXPA05010391A patent/MXPA05010391A/es active IP Right Grant
2005
- 2005-09-27 IL IL171118A patent/IL171118A/en not_active IP Right Cessation
- 2005-10-24 NO NO20054912A patent/NO329997B1/no not_active IP Right Cessation
2012
- 2012-05-29 US US13/482,978 patent/US8389680B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2004087067A3 (fr)	2004-12-29
UA80870C2 (en)	2007-11-12
AU2004226403B2 (en)	2008-12-04
CA2520400C (fr)	2013-02-19
MXPA05010391A (es)	2005-11-04
EP1613340A4 (fr)	2009-07-01
KR20050114264A (ko)	2005-12-05
NO20054912D0 (no)	2005-10-24
DK1613340T3 (da)	2010-08-30
EP1613340B1 (fr)	2010-05-12
ATE467422T1 (de)	2010-05-15
IL171118A (en)	2011-10-31
KR101089145B1 (ko)	2011-12-02
US20120295840A1 (en)	2012-11-22
AU2004226403A1 (en)	2004-10-14
NO20054912L (no)	2005-12-20
CA2520400A1 (fr)	2004-10-14
US8207294B2 (en)	2012-06-26
NZ542900A (en)	2007-06-29
EP1613340A2 (fr)	2006-01-11
BRPI0408892A (pt)	2006-04-11
PL1613340T3 (pl)	2010-10-29
US20070129292A1 (en)	2007-06-07
US8389680B2 (en)	2013-03-05
WO2004087067A2 (fr)	2004-10-14
JP4629033B2 (ja)	2011-02-09
EA200501414A1 (ru)	2006-04-28
JP2006521406A (ja)	2006-09-21
EA008037B1 (ru)	2007-02-27

Legal Events

Date	Code	Title	Description
2013-10-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
Romani et al.	2004	Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling
Legrand	2012	Lactoferrin, a key molecule in immune and inflammatory processes
Actor et al.	2009	Lactoferrin as a natural immune modulator
US8389680B2 (en)	2013-03-05	Treatment of Aspergillus infections with alpha thymosin peptides
Li et al.	2013	The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1–thymopentin fusion peptide and its binding to TLR2
US10953071B2 (en)	2021-03-23	Compositions and methods for treatment of intracellular damage and bacterial infection
CN109069875B (zh)	2021-12-24	产生免疫耐受反应的组合物和方法
Meng et al.	2013	Synergistic effect of methionine encephalin (MENK) combined with pidotimod (PTD) on the maturation of murine dendritic cells (DCs)
US20110294736A1 (en)	2011-12-01	Compounds and methods for the treatment of autoimmune and inflammatory disease
WO2015200469A1 (fr)	2015-12-30	Manf en tant que régulateur du fonctionnement du système immunitaire
RU2461390C2 (ru)	2012-09-20	Иммунологически активные составы
ME02743B (fr)	2010-05-07	Medicament servant au traitement d'infections fongiques, en particulier de l'aspergillose
Song et al.	2013	Maturation inside and outside bone marrow dendritic cells (BMDCs) modulated by interferon-α (IFN-α)
CN100342907C (zh)	2007-10-17	胸腺素α1在制备用于治疗或预防哺乳动物中曲霉菌感染的药物组合物中的应用
Aravindhan et al.	2022	Immunomodulation against
WO2016046419A1 (fr)	2016-03-31	Nouveaux composés immunostimulants
Lu	2004	Acyloxyacyl Hydrolase: Studies on Its Regulation and Function in Mus Musculus
Yawe	2016	Macrophages Are Regulators of Whole Body Metabolism: A Dissertation
US20070041937A1 (en)	2007-02-22	G-csf derivative for inducing immunological tolerance
Johnston et al.	2009	Enhanced Tumor Metastasis in Response to